DE60229727D1 - Methylation-modulierende verbingungen zur intraduktalen behandlung von brustkrebs - Google Patents
Methylation-modulierende verbingungen zur intraduktalen behandlung von brustkrebsInfo
- Publication number
- DE60229727D1 DE60229727D1 DE60229727T DE60229727T DE60229727D1 DE 60229727 D1 DE60229727 D1 DE 60229727D1 DE 60229727 T DE60229727 T DE 60229727T DE 60229727 T DE60229727 T DE 60229727T DE 60229727 D1 DE60229727 D1 DE 60229727D1
- Authority
- DE
- Germany
- Prior art keywords
- breast cancer
- methylation
- intraductal
- modulating conditions
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27976201P | 2001-03-30 | 2001-03-30 | |
US10/101,631 US20020142941A1 (en) | 2001-03-30 | 2002-03-21 | Intraductal treatment targeting methylated promoters in breast cancer |
PCT/US2002/006665 WO2002078716A2 (en) | 2001-03-30 | 2002-03-27 | Methylated promoters for intraductal treatment of breast cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60229727D1 true DE60229727D1 (de) | 2008-12-18 |
Family
ID=26798462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60229727T Expired - Fee Related DE60229727D1 (de) | 2001-03-30 | 2002-03-27 | Methylation-modulierende verbingungen zur intraduktalen behandlung von brustkrebs |
Country Status (8)
Country | Link |
---|---|
US (2) | US20020142941A1 (de) |
EP (1) | EP1372671B1 (de) |
JP (2) | JP2004525151A (de) |
AT (1) | ATE413180T1 (de) |
AU (1) | AU2002247262B2 (de) |
DE (1) | DE60229727D1 (de) |
ES (1) | ES2314041T3 (de) |
WO (1) | WO2002078716A2 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU769853B2 (en) * | 1999-06-11 | 2004-02-05 | Atossa Genetics, Inc. | Gel composition for filing a breast milk duct prior to surgical excision of the duct or other breast tissue |
WO2008098077A2 (en) * | 2007-02-06 | 2008-08-14 | University Of Louisville Research Foundation | Substituted alkine derivatives as anti-cancer agents |
AU2009270849B2 (en) | 2008-07-17 | 2013-11-21 | Micell Technologies, Inc. | Drug delivery medical device |
CA2756386C (en) | 2009-03-23 | 2019-01-15 | Micell Technologies, Inc. | Drug delivery medical device |
CN102292458A (zh) | 2009-04-03 | 2011-12-21 | A&T株式会社 | 大肠肿瘤的检测方法 |
US20120149761A1 (en) * | 2009-08-27 | 2012-06-14 | Atossa Genetics, Inc. | Nucleic acid molecules and uses thereof |
US20130059903A1 (en) * | 2010-03-12 | 2013-03-07 | The Johns Hopkins University | Compositions and Methods for Characterizing Breast Cancer |
ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US20210060052A1 (en) * | 2018-03-15 | 2021-03-04 | Atossa Therapeutics, Inc. | In situ methods of inducing of immune response |
CN111363819A (zh) * | 2020-01-08 | 2020-07-03 | 武汉科技大学 | 一种利用ddPCR技术联合检测诊断乳腺癌的方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5101072A (en) * | 1989-09-06 | 1992-03-31 | Yale University | Sulfonylhydrazines and their use as antineoplastic agents and as antitrypanosomal agents |
US5763415A (en) * | 1995-08-03 | 1998-06-09 | John Hopkins University School Of Medicine | Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer |
US5874416A (en) * | 1997-11-07 | 1999-02-23 | Sheikhnejad; Gholamreza | RAS antisense inhibition |
AU5128999A (en) * | 1998-07-24 | 2000-02-14 | Yeda Research And Development Co. Ltd. | Prevention of metastasis with 5-aza-2'-deoxycytidine |
-
2002
- 2002-03-21 US US10/101,631 patent/US20020142941A1/en not_active Abandoned
- 2002-03-27 AT AT02715041T patent/ATE413180T1/de not_active IP Right Cessation
- 2002-03-27 EP EP02715041A patent/EP1372671B1/de not_active Expired - Lifetime
- 2002-03-27 DE DE60229727T patent/DE60229727D1/de not_active Expired - Fee Related
- 2002-03-27 AU AU2002247262A patent/AU2002247262B2/en not_active Ceased
- 2002-03-27 JP JP2002576981A patent/JP2004525151A/ja active Pending
- 2002-03-27 WO PCT/US2002/006665 patent/WO2002078716A2/en active Application Filing
- 2002-03-27 ES ES02715041T patent/ES2314041T3/es not_active Expired - Lifetime
-
2005
- 2005-08-15 US US11/203,800 patent/US20050272685A1/en not_active Abandoned
-
2008
- 2008-10-23 JP JP2008273409A patent/JP2009096808A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2314041T3 (es) | 2009-03-16 |
ATE413180T1 (de) | 2008-11-15 |
AU2002247262B2 (en) | 2008-09-04 |
JP2004525151A (ja) | 2004-08-19 |
JP2009096808A (ja) | 2009-05-07 |
US20050272685A1 (en) | 2005-12-08 |
WO2002078716A2 (en) | 2002-10-10 |
EP1372671B1 (de) | 2008-11-05 |
WO2002078716A3 (en) | 2002-11-21 |
EP1372671A2 (de) | 2004-01-02 |
US20020142941A1 (en) | 2002-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60229727D1 (de) | Methylation-modulierende verbingungen zur intraduktalen behandlung von brustkrebs | |
DK1556058T3 (da) | Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi | |
DE69830072D1 (de) | Radioaktive zusammensetzungen zur behandlung von prostatatumoren | |
DK1261367T3 (da) | Anvendelse af interleukin-6-antagonister til behandling af östrogenafhængige tumorer | |
ATE323474T1 (de) | Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs | |
PT1038022E (pt) | Avaliacao de doencas relacionadas com o virus papiloma humano | |
ATE501722T1 (de) | Therapeutische behandlung androgenrezeptorbedingter leiden | |
PT1206474E (pt) | Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2 | |
BR0010702A (pt) | Novas quinonas como terapias de doenças | |
ATE478076T1 (de) | Azaxanthonen zur behandlung von tumoren | |
AU3392901A (en) | Proteins | |
CY1110043T1 (el) | 2-αμινοβενζουλ παραγωγα | |
MX2022011163A (es) | Conjugados de polipeptidos de interleucina-2 y sus usos. | |
MXPA02009744A (es) | Uso de fulvestrant en el tratamiento de cancer resistente de mama. | |
CY1111522T1 (el) | 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο | |
DE69927286D1 (de) | Verwendung von humanen prostatazellinien zur behandlung von prostatakrebs | |
PH12016502042A1 (en) | Drug delivery conjugates for treating resistant cancer and for use in combination therapy | |
DE60032333D1 (de) | Zusammensetzungen und verfahren zur intraductalen gentherapie | |
MXPA05008817A (es) | Derivados de esteres lipidos de nucleotidos. | |
DE60111614D1 (de) | Taxan-derivate für die behandlung von krebs | |
ATE544492T1 (de) | Alpha- und beta-emittierende hydroxyapatit- teilchen | |
DE60326348D1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
HK1048263A1 (en) | Medicaments that contain xenogenic oligo-or/and polyribonucleotides. | |
BR0308976A (pt) | Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia | |
WO2005048956A3 (en) | Estradiol-related compounds and methods of use as anti-tumor agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: WINDY HILL MEDICAL INC., LAGUNA HILLS, CALIF., US |
|
8328 | Change in the person/name/address of the agent |
Representative=s name: ELBEL, M., DIPL.-BIOL.UNIV. DR.RER.NAT., PAT.-ANW. |
|
8339 | Ceased/non-payment of the annual fee |